Objective: To evaluate trends in the prevalence of major depressive episodes (MDEs) in Canada during the past 2 decades using data collected in a series of national surveys.
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Clinical Implications
• Perceptions of an epidemic of depression are probably due to increasing awareness of this condition and are not supported by available data.
• Several studies have shown that treatment provision for depression, particularly antidepressant use, has increased. This has not been associated with diminishing prevalence of MDEs.
Limitations
• All of the diagnostic instruments employed in these studies are vulnerable to inaccuracy because of their inability to incorporate clinical judgment into the diagnostic assessment.
• In some surveys, the assessment of MDEs was optional content. Differing trends in various provinces or regions may not have been detected as a result.
• Despite design similarities, considerable heterogeneity (beyond that accounted for by instrument type) was observed.
T emporal trends in mental disorder prevalence have been difficult to discern in epidemiologic studies. Small changes made to the fully structured diagnostic interviews used in these studies can have a large impact on prevalence estimates, 1 such that repeated surveys are generally not directly comparable. Also, structured diagnostic interviews have undergone revisions over the years, as have the algorithms used to interpret them. As a consequence, despite repeated surveys occurring in several countries, there has been little agreement about whether prevalence is changing. In Canada, a simulation study 2 designed as a support tool for policy decisions related to the national mental health strategy adopted an assumption of stable prevalence, using evidence available at the time. 3 Since then, additional data sources have become available, in particular a second national mental health survey. 4 During the past 2 decades in Canada, the prevalence of MDE has been repeatedly assessed by national studies incorporating 1 of 2 instruments. A short form version of the CIDI major depression module (that is, the CIDI-SFMD 5 ) has been repeatedly incorporated, without modification, into a series of general health surveys starting in 1994. Also, 2 national mental health surveys (the CCHS 1.2 and the CCHS-MH), conducted in 2002 and 2012, used a Canadian adaptation of the WMH-CIDI. While some WMH-CIDI modules were modified for the second survey, the MDE module was not. The objective of this study was to evaluate temporal trends in MDE prevalence while incorporating all of these data sources and using meta-regression to account for the use of the 2 different instruments. We sought to address the question of whether the prevalence of MDE is changing over time.
Methods
Our study used data from 3 sources; the NPHS, 6 the general health cycles of the CCHS, 7 and 2 mental health-focused iterations of the CCHS (CCHS 1.2 and CCHS-MH). 4, 8 The NPHS and CCHS are national general health surveys targeting the Canadian household population. The NPHS was a longitudinal study that nevertheless produced crosssectional data files in 1994, 1996, and 1998. 6 This was possible because of a sampling strategy that resulted in the cohort being refreshed with a child and adolescent sample from another survey, so-called buy-in samples from some provinces and the recalculation of sampling weights for use in making cross-sectional estimates. The CCHS consists of a series of general health surveys 7 as well as topically specialized ones. The general health CCHS surveys often included the CIDI-SFMD. 5 The instrument was usually included as optional content, meaning that it was included in the survey interview in some, but not all, provinces. The mental health-focused CCHS surveys, which included a Canadian adaptation of the WMH-CIDI, 9 occurred in 2002 and 2012.
The decision to combine data from these various sources at the survey-estimate level (rather than at the individual level as in a pooled analysis) was motivated by the need to incorporate sampling weights and bootstrap variance estimation to account for design effects, helping to ensure valid estimates of prevalence and of the precision associated with those estimates. The available survey weights were not designed for use in pooled analyses.
Estimates were initially examined graphically using forest plots of the prevalence estimates and associated 95% confidence intervals by province, survey, and year. We examined heterogeneity (I 2 ) and since high levels of heterogeneity (>90%) were observed, meta-analytic estimates were subsequently generated using random effects models. Random effects meta-regression was used to examine changes over time, with adjustment for the measurement strategy employed in the individual surveys. Time was represented in these analyses as years since the initial assessment of MDE prevalence in 1994. This meant that the intercept term in the meta-regression's linear equation represented a baseline estimate (1994), and the slope term represented change per year. As recommended by Higgins and Thompson, 10 permutation tests (with n = 1000 Monte Carlo trials) were used to confirm P values from the meta-regression models. The analyses used Stata's Table 1 summarizes the number of available observations for each of the outcome variables in each survey cycle. Figure 1 presents the annual prevalence estimates and associated 95% confidence interval from each survey. Although considerable heterogeneity is present, there is no visual evidence of increasing prevalence over time.
Results
Prevalence estimates sometimes appeared to be lower in Newfoundland and Labrador, Prince Edward Island, and Quebec, compared with other provinces, but these effects were neither consistent over time nor statistically significant when evaluated in meta-regression models. Also, there was a tendency for the estimates based on the WMH-CIDI to be slightly lower than many of those based on the CIDI-SFMD (Figure 1) , an effect that did not, however, achieve statistical significance (random effects metaregression, β = -0.009, t = 1.19, df = 1, P = 0.26). Lower prevalence with the WMH-CIDI was expected owing to its application of more detailed probes for symptom severity and persistence when compared with the CIDI-SFMD.
The overall pooled annual prevalence was 5.5% (95% CI 4.8% to 6.2%), with an associated tau 2 value from the random effects model of 0.0001 and an I 2 of 97.8%. The addition of time to this model led to an estimated coefficient Survey that was near zero at 0.0004 (95% CI -0.0009 to 0.001) and which was not significantly different from the null value of zero (t = 0.82, df = 1, P = 0.43). Inclusion of time did not decrease the I 2 value, which was 98.0% in this model. In a model containing the time variable, an indicator representing use of the WMH-CIDI instrument again suggested lower prevalence by about 1% with this instrument (β = 0.012), but remained nonsignificant (t = 1.54, df = 1, P = 0.16).
With adjustment for measurement instrument, the time coefficient (β = 0.0007) remained very close to zero and remained nonsignificant (t = 1.28, df = 1, P = 0.24). Because lower estimates with the WMH-CIDI were expected, the meta-regression depicted in Figure 1 includes the relevant indictor term despite its lack of statistical significance.
Results using the permutation test confirmed these results, with neither time (P = 0.43) nor measurement instrument (P = 0.31) being statistically significant. The 95% confidence interval for time, adjusted for measurement strategy, was -0.0006 to 0.0021. In this model, the I 2 value was much the same as that for the overall prevalence estimate at 98.0%.
Discussion
A perception has emerged that the prevalence of this MDE may be increasing over time. This perception may be attributable to an increase in antidepressant use and an increased frequency of self-reported diagnoses of depression, 3 as well as to a greater awareness of depression within the general public. However, examination of prevalence during a long period of time in a set of nationally representative samples in our study did not identify an increase in prevalence.
A limitation of the analysis concerns the precision of the estimated time effect. The slope coefficient for time, adjusted for measurement instrument, was 0.0007, indicating a nonsignificant increase of slightly less than one-tenth of 1% per year. The upper bound of the confidence interval indicated that the data are consistent with an increase as large as 0.2% per year, which could be of public health significance as it could lead to substantial changes over time. However, the effect was not statistically significant in this analysis. The null hypothesis of a zero slope was not rejected at the P < 0.05 level of confidence.
The meta-analytical methods employed weight the pooled estimates according to the inverse of their variance. However, they do not give more weight to the presumably superior measurement instrument, the WMH-CIDI. Therefore, it is important to note that the point estimate in 2012 was 4.7%, very similar to the 4.8% estimate of the 2002 survey, which also used the WMH-CIDI. This observation provides additional support for the conclusion that the annual prevalence of this condition is stable.
Considerable heterogeneity was observed across these studies. This suggests that some factors other than chance had an impact on the prevalence estimates. These factors are unknown but may relate to societal conditions, regional differences, or to measurement artifacts, such as the relative placement of the MDE assessment modules in the survey interviews. However, temporal trends do not seem to be contributing to this heterogeneity.
